Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Canada Postdoctoral Research Award (CPRA) program

University of Manitoba

$140,000.00

Disrupting Endothelial NMDAR Signaling as a Therapeutic Strategy for Group 3 Medulloblastoma

EF 2025-26

Résumé
Brain cancer research often focuses on studying tumor cells in isolation, but these cells interact with their surrounding environment, influencing their growth and response to treatment. This project aims to understand how Group 3 medulloblastoma (G3 MB), an aggressive childhood brain tumour, communicates with nearby blood vessel cells to promote tumor progression. G3 MB is a highly malignant brain tumor that spreads through the spinal cord and has a poor survival rate. Recent research suggests that tumor cells grow near immature blood vessels, forming a specialized environment that helps them maintain their aggressive, stem-like state. The tumor produces high levels of glutamate, a key brain metabolite, which may activate receptors on blood vessel cells, triggering the release of signals that support tumor growth. However, this process remains poorly understood. This study will investigate how tumor-derived glutamate interacts with blood vessel cells and whether blocking this communication can slow tumor progression. Using advanced cell and animal models, genetic modifications, and drug screening, we will identify new treatment strategies. Findings from this work could lead to the development of novel therapies that target tumor-blood vessel interactions, offering hope for improved outcomes in children with this devastating disease.
Programme
Canada Postdoctoral Research Award (CPRA) program
Emplacement
Manitoba, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
537517
Name
Martell Emma L
Region
Manitoba
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Canada Postdoctoral Research Award - A
Projecttitle
Disrupting Endothelial NMDAR Signaling as a Therapeutic Strategy for Group 3 Medulloblastoma
Programtype2
Fellowship Programs
Orgnameinp2
University of Manitoba
Cihramount2
$140,000
Cihrequipment2
$0
Programname2
Canada Postdoctoral Research Award (CPRA) program
Keyworddelim
Cancer Therapy; Cell Signaling; Endothelial Cell Biology; Medulloblastoma; Metabolism; Pediatric Cancer; Tumor Microenvironment
Abstract
Brain cancer research often focuses on studying tumor cells in isolation, but these cells interact with their surrounding environment, influencing their growth and response to treatment. This project aims to understand how Group 3 medulloblastoma (G3 MB), an aggressive childhood brain tumour, communicates with nearby blood vessel cells to promote tumor progression. G3 MB is a highly malignant brain tumor that spreads through the spinal cord and has a poor survival rate. Recent research suggests that tumor cells grow near immature blood vessels, forming a specialized environment that helps them maintain their aggressive, stem-like state. The tumor produces high levels of glutamate, a key brain metabolite, which may activate receptors on blood vessel cells, triggering the release of signals that support tumor growth. However, this process remains poorly understood. This study will investigate how tumor-derived glutamate interacts with blood vessel cells and whether blocking this communication can slow tumor progression. Using advanced cell and animal models, genetic modifications, and drug screening, we will identify new treatment strategies. Findings from this work could lead to the development of novel therapies that target tumor-blood vessel interactions, offering hope for improved outcomes in children with this devastating disease.
Competitiondate
202509
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Martell, Emma L
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $140,000~ $0~